Targeted treatment before and after surgery for lung cancer with BRAF or MET changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving targeted therapy before and after surgery helps people with a specific type of lung cancer (non-small cell lung cancer with a BRAF or MET mutation). The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC) that is stage IB to IIIA (or selected IIIB) and can be removed with surgery.
- Your tumor has a specific gene change called BRAF V600 or MET exon 14 (found through a biopsy or blood test).
- You have not had any previous cancer treatment.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
This trial tests a targeted drug called vebreltinib given before surgery to people with a specific type of non-small cell lung cancer that has a MET gene change. The goal is to see if it can shrink the tumor enough to make surgery more successful.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Hear when a new BRAF V600 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.